453 results on '"Julian, Thomas B"'
Search Results
52. Linking Inflation Differential Across Regions to Unemployment in the Philippines
53. Ductal carcinoma in situ: an overview
54. A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ
55. Does Predicting Positive Nonsentinel Nodes Answer the Question of Axillary Dissection and Provide a Benefit?.
56. CAGS and ACS Evidence Based Reviews in Surgery. 40: Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis
57. Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS
58. Effect of Occult Metastases on Survival in Node-Negative Breast Cancer
59. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).
60. Primary results of NRG Oncology / NSABP B-43: Phase III trial comparing concurrent trastuzumab (T) and radiation therapy (RT) with RT alone for women with HER2-positive ductal carcinoma in situ (DCIS) after lumpectomy.
61. The ongoing evaluation and evolution of breast cancer surgical care
62. Abstract GS5-05: Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery
63. Abstract OT2-02-03: NSABP FB-13: An assessment of the biological and clinical effects of palbociclib with ovarian suppression and letrozole in the neoadjuvant treatment of pts (pts) with premenopausal (preM) estrogen-receptor positive/HER2-negative primary breast cancer
64. Morbidity Results From the NSABP B-32 Trial Comparing Sentinel Lymph Node Dissection Versus Axillary Dissection
65. Surgeon Training, Protocol Compliance, and Technical Outcomes From Breast Cancer Sentinel Lymph Node Randomized Trial
66. Neo-Adjuvant Hormonal Therapy
67. Correlation of the use of axillary ultrasound and lymph node needle biopsy with surgical lymph node pathology in patients with invasive breast cancer
68. NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: A description of the trial
69. Detection of Occult Sentinel Lymph Node Micrometastases by Immunohistochemistry in Breast Cancer: An NSABP Protocol B-32 Quality Assurance Study
70. Magnetic resonance imaging detection and wire localization of an ‘occult’ breast cancer
71. Added Cancer Yield of MRI in Screening the Contralateral Breast of Women Recently Diagnosed With Breast Cancer: Results From the International Breast Magnetic Resonance Consortium (IBMC) Trial
72. Mammographic Density and Breast Cancer After Ductal Carcinoma In Situ
73. Report of the Working Groups on Breast MRI: Report of the Biopsy and Intervention Working Group
74. Report of the Working Groups on Breast MRI: Report of the Breast Cancer Staging Group
75. Practice Patterns of Sentinel Node Biopsy at Five Comprehensive Cancer Centers
76. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer
77. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer.
78. NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC).
79. Followup mammography after breast conservation therapy: Is 3D Tomosynthesis(3DT) worth it?
80. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial
81. Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer
82. Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy
83. NRG Oncology BR005: Phase II trial assessing accuracy of tumor bed biopsies (Bx) in predicting pathologic response in patients (Pts) with clinical/radiological complete response (CR) after neoadjuvant chemotherapy (NCT) in order to explore the feasibility of breast-conserving treatment (BCT) without surgery.
84. NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with positive axillary (PAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC).
85. Linking Inflation Differential Across Regions to Unemployment in the Philippines
86. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology
87. Long-Term Follow-Up Post-Cryosurgery in a Sheep Breast Model
88. Impact evaluation of the agricultural insurance program of the PCIC on agricultural producers in Central Visayas
89. Primary results, NSABP B-35/NRG Oncology: A clinical trial of anastrozole vs tamoxifen in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy A randomized clinical trial
90. Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30
91. NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence free interval (IBCRFI) in patients (pts) with positive axillary (PAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC).
92. Milestone clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP)
93. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy
94. Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy.
95. Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer.
96. Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer.
97. Limited-field and whole-breast hypofractionated radiotherapy: additional considerations
98. The Allegheny general modification of the Harvard breast cosmesis scale for the retreated breast
99. NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence free interval (IBCRFI) in patients (pts) with positive axillary (PAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC).
100. Ductal Carcinoma In Situ of the Breast
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.